IL-YANG PHARM was established in 1946 and has been committed to the corporate philosophy of "Value Creation with Respect for Man's Life and Dignity." The company has played a significant role in the growth of the Korean pharmaceutical industry.

Tags

Infectious Diseases

Respiratory Diseases

Digestive System Disorders

Small molecule drug

Prophylactic vaccine

Inactivated vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	6
Endocrinology and Metabolic Disease	2
Neoplasms	2
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	8
Inactivated vaccine	2
Prophylactic vaccine	2
Multivalent vaccine	1

Top 5 Target	Count

Proton pump	3
Bcr-Abl x PDGFRs	1
hemagglutinin(Influenza virus hemagglutinin glycoproteins)	1
COXs x H1 receptor x α-adrenergic receptor	1
fungal CYP51A1	1

Drugs associated with IlYang Pharmaceutical Co., Ltd.

Ilaprazole/Sodium Bicarbonate

Target

Proton pump

Mechanism

Proton pump inhibitors

Active Org.

IlYang Pharmaceutical Co., Ltd.

Originator Org.

IlYang Pharmaceutical Co., Ltd.

Active Indication

Erosive esophagitis

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

South Korea

First Approval Date04 Mar 2025

Influenza virus vaccine (Il-Yang Pharmaceutical)

Target-

Mechanism

Immunostimulants

Active Org.

IlYang Pharmaceutical Co., Ltd.

Originator Org.

IlYang Pharmaceutical Co., Ltd.

Active Indication

Influenza A virus infection [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

South Korea

First Approval Date04 Jan 2024

Lansoprazole/Sodium Bicarbonate

Target

Proton pump

Mechanism

Proton pump inhibitors

Active Org.

Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd. [+3]

Originator Org.

Beijing Xuze Pharmaceutical Technology Co., Ltd.

Active Indication

Hyperchlorhydria [+5]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

China

First Approval Date30 Sep 2022

Clinical Trials associated with IlYang Pharmaceutical Co., Ltd.

NCT05617651

/ Not yet recruitingPhase 1

Phase 1 Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T in Healthy Adult Volunteers Under Fed Condition

This study evaluate the pharmacokinetic and safety of IY-NT-T in healthy adults

Start Date30 Nov 2024

Sponsor / Collaborator

IlYang Pharmaceutical Co., Ltd.

NCT06665412

/ RecruitingNot Applicable

A Single-arm, Open-label, Multicenter, Investigator-led Observational Study to Evaluate the Efficacy and Safety of Dose Reduction of Radotinib as a First-line Treatment in Patients With Newly Diagnosed Chronic Phase Ph+ Chronic Myeloid Leukemia.

The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects.
The main efficacy is checked by MMR rate by 12 months from IP treatment.

Start Date24 Oct 2024

Sponsor / Collaborator

IlYang Pharmaceutical Co., Ltd.

NCT04381689

/ RecruitingPhase 3

Phase Ⅲ, Randomized, Double-blind, Active Controlled to Evaluate the Immunogenicity and Safety of "IL-YANG Quadrivalent Seasonal Influenza Vaccine" in Healthy Infants From 6 Months to Under 3 Years of Age(≥ 6 Months and < 3 Years)

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and < 3 years)

Start Date23 Oct 2024

Sponsor / Collaborator

IlYang Pharmaceutical Co., Ltd.

100 Clinical Results associated with IlYang Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with IlYang Pharmaceutical Co., Ltd.

Literatures (Medical) associated with IlYang Pharmaceutical Co., Ltd.

01 Sep 2018·European Journal of Clinical PharmacologyQ3 · MEDICINE

Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study

Q3 · MEDICINE

Article

Author: Shin, Jae Soo ; Yoo, Byung Won ; Lee, Jun Yeon ; Kim, Jung Hye ; Park, Min Soo ; Jin, Byung Hak ; Park, Jungsin

PURPOSEIlaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori. The aim of this study was to evaluate pharmacokinetic drug interactions and safety profiles after coadministration of clarithromycin, amoxicillin, and ilaprazole.METHODSA randomised, open-label, one-way crossover, two parallel sequences study was conducted in 32 healthy subjects. In part 1, the subjects received a single dose of ilaprazole 10 mg in period 1 and clarithromycin 500 mg and amoxicillin 1000 mg twice daily for 6 days in period 2. In part 2, the subjects received clarithromycin 500 mg and amoxicillin 1000 mg once in period 1 and ilaprazole 10 mg twice daily for 6 days in period 2. In both sequences, the three drugs were coadministrated once on day 5 in period 2. Pharmacokinetic evaluations of ilaprazole (part 1), and clarithromycin and amoxicillin (part 2) were conducted.RESULTSTwenty-eight subjects completed the study. For ilaprazole, the peak concentration (C_max) slightly decreased from 479 (ilaprazole alone) to 446 ng/mL (triple therapy) [Geometric least square mean ratio (90% confidence interval), 0.93 (0.70-1.22)]. The area under the concentration-time curve from 0 h to the last measurable concentration (AUC_last) slightly increased from 3301 to 3538 μg·h/mL [1.07 (0.85-1.35)]. For clarithromycin, the C_max slightly decreased from 1.87 to 1.72 μg/mL [0.90 (0.70-1.15)], and AUC_last slightly increased from 14.6 to 16.5 μg·h/mL [1.09 (0.87-1.37)]. For amoxicillin, the C_max slightly decreased from 9.37 to 8.14 μg/mL [0.86 (0.74-1.01)], and AUC_last slightly decreased from 27.9 to 26.7 μg·h/mL [0.98 (0.83-1.16)]. These changes in the PK parameters of each drug were not statistically significant.CONCLUSIONSThe coadministration of ilaprazole, clarithromycin, and amoxicillin was tolerable and did not cause a significant PK drug interaction. Thus, a triple therapy regimen comprising ilaprazole, clarithromycin, and amoxicillin may be an option for the eradication of H. pylori. Clinicaltrials.gov number: NCT02998437.

01 Jul 2018·Human Molecular GeneticsQ2 · BIOLOGY

The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model

Q2 · BIOLOGY

Article

Author: Kim, Sangjune ; Cho, Dae Jin ; Yun, Hyo Jung ; Lee, Seulki ; Shin, Jae Soo ; Lee, Saebom ; Park, Yong Joo ; Lee, Gong Yeal ; Kim, Dong Yeon ; Kwon, Seung-Hwan ; Ko, Han Seok ; Yun, Seung Pil ; Kim, Donghoon ; Jung, Eun Ah ; Park, Jae Hong ; Ju, Hyun Soo ; Kim, Wonjoong Richard

Accumulating evidence suggests that the non-receptor tyrosine kinase c-Abl plays an important role in the progression of Parkinson's disease (PD) and c-Abl inhibition could be neuroprotective in PD and related α-synucleinopathies. Nilotinib, a c-Abl inhibitor, has shown improved motor and cognitive symptoms in PD patients. However, issues concerning blood-brain barrier (BBB) penetration, lack of selectivity and safety still remain. Radotinib HCl is a selective Bcr-Abl kinase inhibitor that not only effectively access the brain, but also exhibits greater pharmacokinetic properties and safety profiles compared to Nilotinib and other c-Abl inhibitors. Here, we show the neuroprotective efficacy of Radotinib HCl, a brain penetrant c-Abl inhibitor, in a pre-clinical model of PD. Importantly, in vitro studies demonstrate that the treatment of Radotinib HCl protects the α-synuclein preformed fibrils (PFF)-induced neuronal toxicity, reduces the α-synuclein PFF-induced Lewy bodies (LB)/Lewy neurites (LN)-like pathology and inhibits the α-synuclein PFF-induced c-Abl activation in primary cortical neurons. Furthermore, administration of Radotinib HCl inhibits c-Abl activation and prevents dopaminergic neuron loss, neuroinflammation and behavioral deficits following α-synuclein PFF-induced toxicity in vivo. Taken together, our findings indicate that Radotinib HCl has beneficial neuroprotective effects in PD and provides an evidence that selective and brain permeable c-Abl inhibitors can be potential therapeutic agents for the treatment of PD and related α-synucleinopathies.

02 Dec 2016·Blood

Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia

Author: Lee, Jangik I ; Noh, Hayeon ; Zang, Dae Young ; Shin, Jae Soo ; Jung, Su Young ; Kwak, Jae-Yong ; Kim, Dong-Wook ; Oh, Suk Joong ; Do, Young Rok ; Jo, Dae Jin ; Kim, Sung-Hyun ; Park, Hye Lin

AbstractBackground: Radotinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia in chronic phase (CP-CML). It is typically administered as a fixed dose; however, a subanalysis of the Phase 2 study (Leuk Lymphoma. DOI 10.3109/10428194.2015.1113278) demonstrated that as the dose adjusted for body weight (Dose/BW) increased the risk of dose-limiting toxicity (DLT) significantly.Aims: To assess the impact of Dose/BW of radotinib on the occurrence of DLT as well as on the achievement of major molecular response (MMR) using the clinical data obtained from the Phase 3 studyMethods: The Phase 3 study involved 160 CP-CML patients who were randomly assigned to a fixed dose of radotinib 300 mg BID or 400 mg BID regardless of BW. The authors performed a logistic regression analysis to evaluate the relationship between daily Dose/BW and the probability of achieving MMR at 12 months as well as experiencing DLT by 12 months. Chi-square test and Kaplan-Meier analysis (log-rank test) were utilized to compare the incidence of MMR and DLT, respectively, according to specific Dose/BW cut-offs.Results: Efficacy. Dose/BW of radotinib was negatively associated with the rate of MMR when controlled for gender (p = 0.033). That is, increasing Dose/BW rather decreased the likelihood of achieving MMR. More specifically, patients who received ≥13 mg/kg/d showed a significantly lower rate of MMR at 12 months (35%) than those who received <13 mg/kg/d (56%) (p = 0.045). Safety. Dose/BW of radotinib was positively associated with the rate of DLT (p = 0.003). A Dose/BW cut-off 13 mg/kg/d yielded the largest difference in the rate of DLT, such that the patients who received ≥13 mg/kg/d had a substantially higher rate of DLT (91%) than those who received <13 mg/kg/d (57%) (p <0.001). The time at which 50% of patients experienced their first DLT was also much earlier in the ≥13 mg/kg/d group (83 days) than in the <13 mg/kg/d group (194 days) (p <0.001).Conclusion: Dose adjustment of radotinib based on BW is warranted so as not to exceed 13 mg/kg/d. Therefore, a two-tier weight-based dosing regimen was developed: radotinib 300 mg BID for patients who weigh 60 kg or less, and 400 mg BID for patients who weigh more than 60 kg. A prospective clinical trial would be needed to confirm the efficacy and safety of this new dosing regimen.DisclosuresNoh: Il-Yang Pharmaceutical: Research Funding. Jung:Il-Yang Pharmaceutical: Research Funding. Park:Il-Yang Pharmaceutical: Employment. Jo:Il-Yang Pharmaceutical: Employment. Shin:Il-Yang Pharmaceutical: Employment. Kim:BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; ILYANG: Consultancy, Honoraria, Research Funding. Lee:Il-Yang Pharmaceutical: Research Funding.

News (Medical) associated with IlYang Pharmaceutical Co., Ltd.

13 Mar 2018

·www.bioportfolio.com

Ilyang Pharmaceutical Co Ltd 007570 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

Summary Ilyang Pharmaceutical Co Ltd Ilyang Pharma is a provider of medicines, food, cosmetics and antacid raw materials. The company provides ETC, over the counter and sanitary aid medicines. It manufactures and distributes a wide range of products in the areas of anticancer, antibiotics, antifungal drugs, liver disease, dermatology, neurology and digestive system, among others. Ilyang Pharma also offers health drinks, beverages, vaccines, supplements, skin protection creams, clinical liquids and clinic cream, among others. Its cosmetics are used for skin protection, moisture in the skin, temporary shrinkage of pores, supply moisture and elasticity, and improve damaged skin. Ilyang Pharma is headquartered in Yongin, South Korea. Ilyang Pharmaceutical Co Ltd 007570 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

VaccineAcquisition

100 Deals associated with IlYang Pharmaceutical Co., Ltd.

100 Translational Medicine associated with IlYang Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ilaprazole ( Proton pump )	Erosive esophagitis More	Approved
Influenza virus vaccine trivalent(Il-Yang Pharmaceutical Co., Ltd.)	Influenza, Human More	Approved
Terazosin Hydrochloride ( α1A-AR )	Prostatic Hyperplasia More	Approved
Influenza virus vaccine (Il-Yang Pharmaceutical)	Influenza A virus infection More	Approved
Radotinib Dihydrochloride ( Bcr-Abl x PDGFRs )	Philadelphia chromosome positive chronic myelogenous leukemia More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis